XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) (including noncontrolling interests) $ 11,358 $ (3,513)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization of property, plant and equipment 390 399
Amortization of intangible assets 62 60
Amortization of operating lease right-of-use assets 130
Amortization of debt issuance costs and discount 135 159
Gain on sale and disposal of assets (4)
Stock-based payment of consulting services 75
Stock-based compensation 713 751
Changes in assets and liabilities:    
Accounts receivable (280) 55
Inventories (554) 209
Prepaid expenses and other current assets (821) (137)
Accounts payable, accrued expenses and other liabilities 158 106
Accrued payroll and related liabilities (1,191) (167)
Deferred revenue and customer deposits 240 44
NET CASH USED IN OPERATING ACTIVITIES (1,476) (965)
CASH FLOWS FROM INVESTING ACTIVITIES    
Repayment of note receivable 4
Proceeds on sale and disposal of assets 4
Investment in patent and trademark assets (115) (76)
Purchases of property, plant and equipment (213) (192)
NET CASH USED IN INVESTING ACTIVITIES (324) (264)
CASH FLOWS FROM FINANCING ACTIVITIES    
Payments on finance lease obligations (185) (167)
Payments on Park deferred acquisition obligation (53)
Principal payments on note payable (750)
Net proceeds from ATM sales of common stock 122
Net proceeds from exercise of warrants 162
NET CASH USED IN FINANCING ACTIVITIES (773) (98)
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (2,573) (1,327)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 6,838 4,219
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 4,265 2,892
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH    
Cash and cash equivalents 4,065 2,692
Restricted cash 200 200
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD 4,265 2,892
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for income taxes 2
Cash paid for interest 467 483
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Issuance of common stock for consulting services, included in accounts payable and accrued expenses 108
Changes in accrued property and equipment purchases 5
Acquisition of property, plant and equipment with finance lease obligations 40
Eton Pharmaceuticals [Member]    
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Investment gain from and equity in net loss (6,580) 1,069
Melt Pharmaceuticals [Member]    
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Investment gain from and equity in net loss (5,525)
Surface Pharmaceuticals [Member]    
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Investment gain from and equity in net loss $ 243